2026-05-21T23:03:35Zhttps://repisalud.isciii.es/rest/oai/requestoai:repisalud.isciii.es:20.500.12105/185862024-02-27T14:57:53Zcom_20.500.12105_15322com_20.500.12105_2051col_20.500.12105_16927
Repisalud
author
Godoy-Ortiz, Ana
author
Alba-Bernal, Alfonso
author
Pascual, Javier
author
Comino-Méndez, Iñaki
author
Alba, Emilio
2024-02-27T14:57:53Z
2024-02-27T14:57:53Z
2022-01-24
10.3390/cancers14030587
2072-6694
Cancers
http://hdl.handle.net/10668/20870
35158855
http://hdl.handle.net/20.500.12105/18586
Invasive breast cancer (BC) is the most common cancer in women with a slightly increasing yearly incidence. BC immunohistochemical characterisation is a crucial tool to define the intrinsic nature of each tumour and personalise BC patients' clinical management. In this regard, the characterisation of human epidermal growth factor receptor 2 (HER2) status guides physicians to treat with therapies tailored to this membrane receptor. Standardly, a tumour solid biopsy is therefore required, which is an invasive procedure and has difficulties to provide the complete molecular picture of the tumour. To complement these standard-of-care approaches, liquid biopsy is a validated methodology to obtain circulating tumour components such as circulating tumour DNA (ctDNA) and circulating tumour cells (CTCs) from body fluids in an easy-to-perform minimal-invasive manner. However, its clinical validity in cancer is still to be demonstrated. This review focusses on the utilisation of both ctDNA and CTCs in early and metastatic HER2-positive BC tumours. We discuss recently published studies deciphering the capacity of liquid biopsy to determine the response to neoadjuvant and adjuvant therapies as well as to predict patients' outcomes.
eng
HER2-positive breast cancer
circulating-tumour DNA
circulating-tumour cells
early breast cancer
liquid biopsy
metastatic breast cancer
Unveiling the Potential of Liquid Biopsy in HER2-Positive Breast Cancer Management.
research article